As CCT196969 has been suggested as a potential second line treatment for BRAF inhibitor resistant melanoma and first line therapy for NRAS- and BRAF-mutated melanoma [24], combination therapy with PI3K inhibitors should be investigated in the future. This evidence concerns the gene NRAS and melanoma.